- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00016250
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
A Randomized Phase II Study of Two Shcedules of Ro 31-7453 in Patients With Metastatic (Dukes' D) Colorectal Carcinoma (CRC) Who Have Failed Both Fluoropyrimidine and Irinotecan Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of Ro 31-7453 in treating patients who have recurrent or refractory metastatic colorectal cancer.
Descripción general del estudio
Descripción detallada
OBJECTIVES:
- Compare the objective disease rate of patients with recurrent or refractory metastatic colorectal cancer treated with two dose schedules of Ro 31-7453.
- Compare the safety and tolerability of these regimens in these patients.
- Compare the response duration in patients treated with these regimens.
- Compare the time to progression and time to treatment failure in patients treated with these regimens.
- Determine the pharmacokinetic profiles of Ro 31-7453 and its major metabolites in these patients.
- Compare the overall survival of patients treated with these regimens.
OUTLINE: This is a randomized, open label, multicenter study. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive oral Ro 31-7453 twice daily on days 1-4. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral Ro 31-7453 twice daily on days 1-14. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 28 days and then every 3 months.
PROJECTED ACCRUAL: Approximately 160 patients (49 per treatment arm plus 61 additional patients in the arm determined to be most effective) will be accrued for this study within 1 year.
Tipo de estudio
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
- Histologically confirmed metastatic adenocarcinoma of the colon or rectum
Bidimensionally measurable disease
- At least 2.0 x 2.0 cm
Failed prior fluoropyrimidine and irinotecan chemotherapy in adjuvant or metastatic setting
- Must have had disease progression while receiving chemotherapy OR
- If received fluorouracil with or without irinotecan in adjuvant setting, must also have failed therapy with these agents in metastatic setting (unless manifesting metastatic disease during adjuvant therapy)
- No known CNS metastases
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 70-100%
Life expectancy:
- Not specified
Hematopoietic:
- Hemoglobin at least 9 g/dL
- Absolute neutrophil count at least 1,500/mm^3
- WBC at least 3,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)
- Alkaline phosphatase no greater than 2.5 ULN (5 times ULN if bone or liver metastases present)
Renal:
- Creatinine no greater than 1.5 times ULN
Cardiovascular:
- No New York Heart Association class III or IV congestive heart failure
- No myocardial infarction within the past 6 months
Gastrointestinal:
- No bowel obstruction
- No active uncontrolled malabsorption syndrome
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infection
- No other prior malignancy within the past 5 years except carcinoma in situ of the cervix or non-melanoma skin cancer
- No other active cancers, including stable disease on adjuvant therapy
- No other medical condition that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Chemotherapy
- At least 2 weeks since prior biologic therapy and recovered
Chemotherapy:
- See Disease Characteristics
- No more than 2 prior cytotoxic chemotherapy regimens for metastatic disease
- Monoclonal antibody (MOAB) therapy and antiangiogenic agents not included as prior cytotoxic chemotherapy
- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
Endocrine therapy:
- Not specified
Radiotherapy:
- At least 3 weeks since prior radiotherapy and recovered
Surgery:
- No prior total gastrectomy
Other:
- No other concurrent investigational agents
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Enmascaramiento: Ninguno (etiqueta abierta)
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 00-139
- CDR0000068613 (Identificador de registro: PDQ (Physician Data Query))
- ROCHE-16113
- ROCHE-RO31-7453
- NCI-G01-1945
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer colonrectal
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre MKC-1
-
CASI Pharmaceuticals, Inc.TerminadoCancer de pancreasEstados Unidos
-
CASI Pharmaceuticals, Inc.TerminadoMielodisplasia | Neoplasias malignas hematológicas | Metaplasia mieloide agnogénicaCanadá
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)TerminadoTumor sólido adulto no especificado, protocolo específicoEstados Unidos
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)TerminadoTumor sólido adulto no especificado, protocolo específicoEstados Unidos
-
CASI Pharmaceuticals, Inc.TerminadoCáncer de mamaEstados Unidos
-
CASI Pharmaceuticals, Inc.TerminadoCáncer de pulmón de células no pequeñas | Cáncer avanzadoEstados Unidos
-
Statens Serum InstitutTerminadoInmunización ActivaPolonia
-
Orasis Pharmaceuticals Ltd.Terminado
-
University of ThessalyTerminado
-
University of Sao Paulo General HospitalTerminadoSíndrome de vejiga hiperactivaBrasil